Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Mechanisms Of Immune Escape In The Cancer Immune Cycle.
S. Tang, Q. Ning, L. Yang, Zhong-cheng Mo, S. Tang
Published 2020 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Cancer is a critical issue globally with high incidence and mortality, imposing great burden on the society. Although great progress has been made in immunotherapy based on immune checkpoint, only a subset of patients responds to this treatment, suggesting that cancer immune evasion is still a major barrier in current immunotherapy. There are a series of factors contributing to immune evasion despite in an immunocompetent environment. Given that these factors are involved in different steps of the cancer immune cycle. In this review, we discuss the mechanisms of immune escape in each step of the cancer immune cycle and then present therapeutic strategies for overcoming immune escape, with the potential to better understand the determinants of immune escape and make anti-tumor immunity more effective.
This paper references
Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman (2018)
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
N. Ready (2019)
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Y. Que (2019)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
T. Mitchell (2018)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
J. Havel (2019)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
J. Wallin (2016)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
S. Wei (2018)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
L. Andrews (2019)
Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors
Gregory T. Motz (2014)
Dendritic cells in a mature age
C. R. E. Sousa (2006)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
A. Sharma (2018)
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Carino Gurjao (2019)
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.
Rikke B. Holmgaard (2015)
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Yosuke Togashi (2019)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U. Sahin (2017)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
M. Hellmann (2018)
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer
C. Lin (2019)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
P. Sharma (2017)
Next-generation regulatory T cell therapy
Leonardo M. R. Ferreira (2019)
Neoantigen landscape dynamics during human melanoma–T cell interactions
E. Verdegaal (2016)
Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition
Yosuke Shionoya (2017)
Cancer immunoediting and resistance to T cell-based immunotherapy
J. S. O’Donnell (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
M. Hellmann (2018)
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
K. Kunimasa (2020)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Q. Zhang (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
R. Huang (2017)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
V. Boussiotis (2016)
Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
S. Ostrand-Rosenberg (2018)
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.
M. Gato-Cañas (2017)
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Ai-lin Li (2018)
Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia
Shannon L Maude (2018)
IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.
K. Bishnupuri (2019)
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
K. Kurose (2015)
Immunoregulatory functions of VISTA
Elizabeth Nowak (2017)
TIM-3 expression and its association with overall survival in primary osteosarcoma
Feifei Pu (2019)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D. Fukumura (2018)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du (2018)
Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion
Mohammad Sultan (2018)
Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance.
R. Tang (2019)
Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer
Baoying Hu (2020)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama (2016)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
S. E. Josefsson (2017)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
F. Vari (2018)
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
Yasuko Tada (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming (2018)
TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer
Agnes Ling (2017)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
An immunogenic personal neoantigen vaccine for patients with melanoma
P. Ott (2017)
Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer Patients
M. Kobayashi (2018)
VEGF in Signaling and Disease: Beyond Discovery and Development
R. Apte (2019)
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta (2018)
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
J. Liu (2018)
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
S. H. Kim (2017)
Knockdown of endothelin receptor B inhibits the progression of triple‐negative breast cancer
X. Gu (2019)
Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade
M. Postow (2018)
Cancer immunotherapy using checkpoint blockade
A. Ribas (2018)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
V. Anagnostou (2017)
LAG3 (CD223) as a cancer immunotherapy target
L. Andrews (2017)
Pembrolizumab for Early Triple-Negative Breast Cancer.
P. Schmid (2020)
Tumor exosomes block dendritic cells maturation to decrease the T cell immune response.
Yongling Ning (2018)
Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer
F. Veglia (2017)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.
T. Azuma (2008)
Chimeric Antigen Receptor Therapy.
C. June (2018)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
A. Anderson (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros (2016)
Interleukin 35: Inhibitory regulator in monocyte‐derived dendritic cell maturation and activation
X. Chen (2018)
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Zhuting Hu (2018)
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients.
D. Vasquez-Dunddel (2013)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston (2019)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont (2015)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
P. Di Gennaro (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Jae Eun Cheong (2018)
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
David H. Munn (2005)
Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas
S. Nakashima (2015)
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells
Yosuke Ohno (2015)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun (2018)
TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo
Srimoyee Ghosh (2018)
CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
L. Shi (2017)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
K. Jung (2019)
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
K. Yonesaka (2018)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte (2019)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman (2017)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
R. Buckanovich (2008)
Treg-mediated acquired resistance to immune checkpoint inhibitors.
R. Saleh (2019)
Interleukin‐6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy
H. Kitamura (2017)
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Y. Kong (2016)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
A. Hung (2018)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
T. Voron (2015)
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
E. Burova (2019)
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
V. Prima (2017)
TIGIT predominantly regulates the immune response via regulatory T cells.
S. Kurtuluş (2015)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N. McGranahan (2016)
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Varun Sasidharan Nair (2018)
PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
M. Nakano (2018)
Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma
S. Neelapu (2017)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Y. Zhu (2014)
Targeting neoantigens to augment antitumour immunity
M. Yarchoan (2017)
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
Takuma Matoba (2019)
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
W. He (2017)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
The effects of Tim-3 activation on T-cells in gastric cancer progression
J. Yu (2019)
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Y. Liu (2018)
B7-H4, a promising target for immunotherapy.
J. Wang (2019)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
G. Beatty (2014)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
P. Robbins (2011)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
TIM3 comes of age as an inhibitory receptor
Y. Wolf (2019)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M. Zaretsky (2016)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
J. Wang (2019)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.
G. Prendergast (2018)
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer
I. Yasinska (2019)
Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
L. Wu (2019)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh (2017)
An essential role for IL-2 receptor in regulatory T cell function
T. Chinen (2016)
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
Nicholas A. Taylor (2017)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm (2019)
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
S. Burugu (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
S. Gettinger (2017)
Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape
Fatima Ahmetlić (2019)
Tumour-associated macrophages as treatment targets in oncology
A. Mantovani (2017)
Oncology meets immunology: the cancer-immunity cycle.
D. Chen (2013)
TIGIT: a novel immunotherapy target moving from bench to bedside
Benjamin L Solomon (2018)
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
G. Gibney (2019)
The diverse functions of the PD1 inhibitory pathway
A. Sharpe (2018)
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.
A. Dirkx (2003)
Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice
Min-Jung Park (2018)
Tumor-Repopulating Cells Induce PD-1 Expression in CD8+ T Cells by Transferring Kynurenine and AhR Activation.
Y. Liu (2018)
Checkpoint inhibitor immunotherapy in kidney cancer
Wenxin Xu (2020)
CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.
Mengjie Wang (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan (2018)
TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
X. Zhang (2019)
New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
D. Mittal (2014)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
M. Platten (2019)
This paper is referenced by
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
S. Sarin (2020)